Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1998 1
2000 1
2001 2
2002 1
2003 3
2004 4
2005 1
2006 4
2007 7
2008 4
2009 4
2010 16
2011 9
2012 14
2013 17
2014 11
2015 12
2016 14
2017 17
2018 10
2019 16
2020 12
2021 17
2022 6
Text availability
Article attribute
Article type
Publication date

Search Results

184 results
Results by year
Filters applied: . Clear all
Page 1
Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group.
[No authors listed] [No authors listed] Mov Disord. 1996 Mar;11(2):136-42. doi: 10.1002/mds.870110204. Mov Disord. 1996. PMID: 8684382
The Unified Huntington's Disease Rating Scale (UHDRS) was developed as a clinical rating scale to assess four domains of clinical performance and capacity in HD: motor function, cognitive function, behavioral abnormalities, and functional capacity. We assessed the internal …
The Unified Huntington's Disease Rating Scale (UHDRS) was developed as a clinical rating scale to assess four domains of clinical per …
Huntington Study Group Abstracts 2020.
[No authors listed] [No authors listed] Neurotherapeutics. 2020 Dec;17(Suppl 1):1-41. doi: 10.1007/s13311-020-00945-z. Neurotherapeutics. 2020. PMID: 33083994 Free PMC article. No abstract available.
Treatment of Tardive Dyskinesia.
Bashir HH, Jankovic J. Bashir HH, et al. Neurol Clin. 2020 May;38(2):379-396. doi: 10.1016/j.ncl.2020.01.004. Epub 2020 Feb 28. Neurol Clin. 2020. PMID: 32279716 Review.
Correction to: Huntington Study Group Abstracts 2020.
[No authors listed] [No authors listed] Neurotherapeutics. 2020 Dec;17(Suppl 1):42. doi: 10.1007/s13311-020-00970-y. Neurotherapeutics. 2020. PMID: 33200289 Free PMC article. No abstract available.
CAG Repeat Not Polyglutamine Length Determines Timing of Huntington's Disease Onset.
Genetic Modifiers of Huntington’s Disease (GeM-HD) Consortium. Electronic address: gusella@helix.mgh.harvard.edu; Genetic Modifiers of Huntington’s Disease (GeM-HD) Consortium. Genetic Modifiers of Huntington’s Disease (GeM-HD) Consortium. Electronic address: gusella@helix.mgh.harvard.edu, et al. Cell. 2019 Aug 8;178(4):887-900.e14. doi: 10.1016/j.cell.2019.06.036. Cell. 2019. PMID: 31398342 Free PMC article.
Variable, glutamine-encoding, CAA interruptions indicate that a property of the uninterrupted HTT CAG repeat sequence, distinct from the length of huntingtin's polyglutamine segment, dictates the rate at which Huntington's disease (HD) develops. The timing of onset shows n …
Variable, glutamine-encoding, CAA interruptions indicate that a property of the uninterrupted HTT CAG repeat sequence, distinct from the len …
Burden of Neurological Disorders Across the US From 1990-2017: A Global Burden of Disease Study.
GBD 2017 US Neurological Disorders Collaborators, Feigin VL, Vos T, Alahdab F, Amit AML, Bärnighausen TW, Beghi E, Beheshti M, Chavan PP, Criqui MH, Desai R, Dhamminda Dharmaratne S, Dorsey ER, Wilder Eagan A, Elgendy IY, Filip I, Giampaoli S, Giussani G, Hafezi-Nejad N, Hole MK, Ikeda T, Owens Johnson C, Kalani R, Khatab K, Khubchandani J, Kim D, Koroshetz WJ, Krishnamoorthy V, Krishnamurthi RV, Liu X, Lo WD, Logroscino G, Mensah GA, Miller TR, Mohammed S, Mokdad AH, Moradi-Lakeh M, Morrison SD, Shivamurthy VKN, Naghavi M, Nichols E, Norrving B, Odell CM, Pupillo E, Radfar A, Roth GA, Shafieesabet A, Sheikh A, Sheikhbahaei S, Shin JI, Singh JA, Steiner TJ, Stovner LJ, Wallin MT, Weiss J, Wu C, Zunt JR, Adelson JD, Murray CJL. GBD 2017 US Neurological Disorders Collaborators, et al. JAMA Neurol. 2021 Feb 1;78(2):165-176. doi: 10.1001/jamaneurol.2020.4152. JAMA Neurol. 2021. PMID: 33136137 Free PMC article.
DESIGN, SETTING, AND PARTICIPANTS: This is a systematic analysis of the Global Burden of Disease (GBD) 2017 study. Data on incidence, prevalence, mortality, and disability-adjusted life-years (DALYs) of major neurological disorders were derived from the GBD 2017 study …
DESIGN, SETTING, AND PARTICIPANTS: This is a systematic analysis of the Global Burden of Disease (GBD) 2017 study. Data on incidence, …
Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial.
Huntington Study Group, Frank S, Testa CM, Stamler D, Kayson E, Davis C, Edmondson MC, Kinel S, Leavitt B, Oakes D, O'Neill C, Vaughan C, Goldstein J, Herzog M, Snively V, Whaley J, Wong C, Suter G, Jankovic J, Jimenez-Shahed J, Hunter C, Claassen DO, Roman OC, Sung V, Smith J, Janicki S, Clouse R, Saint-Hilaire M, Hohler A, Turpin D, James RC, Rodriguez R, Rizer K, Anderson KE, Heller H, Carlson A, Criswell S, Racette BA, Revilla FJ, Nucifora F Jr, Margolis RL, Ong M, Mendis T, Mendis N, Singer C, Quesada M, Paulsen JS, Brashers-Krug T, Miller A, Kerr J, Dubinsky RM, Gray C, Factor SA, Sperin E, Molho E, Eglow M, Evans S, Kumar R, Reeves C, Samii A, Chouinard S, Beland M, Scott BL, Hickey PT, Esmail S, Fung WL, Gibbons C, Qi L, Colcher A, Hackmyer C, McGarry A, Klos K, Gudesblatt M, Fafard L, Graffitti L, Schneider DP, Dhall R, Wojcieszek JM, LaFaver K, Duker A, Neefus E, Wilson-Perez H, Shprecher D, Wall P, Blindauer KA, Wheeler L, Boyd JT, Houston E, Farbman ES, Agarwal P, Eberly SW, Watts A, Tariot PN, Feigin A, Evans S, Beck C, Orme C, Edicola J, Christopher E. Huntington Study Group, et al. JAMA. 2016 Jul 5;316(1):40-50. doi: 10.1001/jama.2016.8655. JAMA. 2016. PMID: 27380342 Free article. Clinical Trial.
OBJECTIVE: To evaluate efficacy and safety of deutetrabenazine treatment to control chorea associated with Huntington disease. DESIGN, SETTING, AND PARTICIPANTS: Ninety ambulatory adults diagnosed with manifest Huntington disease and a baseline total maximal chorea …
OBJECTIVE: To evaluate efficacy and safety of deutetrabenazine treatment to control chorea associated with Huntington disease. DESIGN …
Phenotype-genotype discrepancies in the prospective Huntington at-risk observational study.
Shoulson I, Eberly S, Oakes D, Kayson E, Young AB; PHAROS Investigators. Shoulson I, et al. Ann Clin Transl Neurol. 2019 May 1;6(6):1046-1052. doi: 10.1002/acn3.781. eCollection 2019 Jun. Ann Clin Transl Neurol. 2019. PMID: 31211168 Free PMC article.
METHODS: We examined the prospective clinical assessments of investigators who were kept unaware of individual CAG lengths in the Prospective Huntington At-Risk Observational Study (PHAROS) who enrolled and followed undiagnosed adults at risk for HD who chose not to …
METHODS: We examined the prospective clinical assessments of investigators who were kept unaware of individual CAG lengths in the Prospectiv …
184 results